Brown, Lisle/Cummings’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.18M Buy
59,204
+109
+0.2% +$5.17K 0.54% 44
2025
Q4
$3.01M Buy
59,095
+4,212
+8% +$215K 0.74% 35
2025
Q3
$3.05M Sell
54,883
-1,171
-2% -$68.5K 0.78% 32
2025
Q2
$3.87M Buy
56,054
+125
+0.2% +$8.5K 1.03% 23
2025
Q1
$3.88M Buy
55,929
+7,071
+14% +$584K 1.13% 20
2024
Q4
$4.2M Sell
48,858
-1,337
-3% -$145K 1.25% 18
2024
Q3
$5.98M Buy
50,195
+7,200
+17% +$960K 1.82% 10
2024
Q2
$6.14M Sell
42,995
-1,070
-2% -$142K 2% 9
2024
Q1
$5.66M Sell
44,065
-225
-0.5% -$26.8K 1.92% 9
2023
Q4
$4.58M Buy
44,290
+7,000
+19% +$692K 1.7% 10
2023
Q3
$3.39M Buy
37,290
+3,700
+11% +$326K 1.53% 15
2023
Q2
$2.72M Sell
33,590
-430
-1% -$35.1K 1.22% 21
2023
Q1
$2.71M Sell
34,020
-7,430
-18% -$527K 1.37% 17
2022
Q4
$2.8M Hold
41,450
1.51% 16
2022
Q3
$2.06M Sell
41,450
-250
-0.6% -$13.4K 1.21% 20
2022
Q2
$2.32M Sell
41,700
-450
-1% -$25K 1.29% 19
2022
Q1
$2.34M Buy
42,150
+4,800
+13% +$246K 1.12% 21
2021
Q4
$2.09M Buy
+37,350
New +$2.02M 1.05% 21

Other funds holding NVO

Brown, Lisle/Cummings's NVO Position: Q1 2026 in Review

Brown, Lisle/Cummings increased its Novo Nordisk (NVO) stake by 0.18% in Q1 2026, buying an estimated $5.17K and bringing the position to 59,204 shares worth $2.18M. The position accounts for 0.54% of the portfolio, ranked #44.

Brown, Lisle/Cummings first reported a position in NVO in Q4 2021 and has held it in 18 quarters since. The position peaked at $6.14M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Brown, Lisle/Cummings held 59,204 shares of Novo Nordisk worth $2.18M as of Q1 2026.
  • Brown, Lisle/Cummings bought 109 Novo Nordisk shares in Q1 2026, an estimated $5.17K.
  • Novo Nordisk made up 0.54% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #44 holding.
  • Brown, Lisle/Cummings first reported a position in Novo Nordisk in Q4 2021 and has held it in 18 quarters since.
  • Brown, Lisle/Cummings's Novo Nordisk position peaked at $6.14M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.